These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 34350048)

  • 1. Recent advances with liposomes as drug carriers for treatment of neurodegenerative diseases.
    Seo MW; Park TE
    Biomed Eng Lett; 2021 Aug; 11(3):211-216. PubMed ID: 34350048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease).
    Spuch C; Navarro C
    J Drug Deliv; 2011; 2011():469679. PubMed ID: 22203906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Research progress on liposome and nanomicelle targeted drug delivery system across blood-brain barrier].
    Yang X; Zou LH; Ding WY; Zhang ZB; Chen JQ; Li JL; Feng HL; Li YY; Tang L; Feng JF
    Zhongguo Zhong Yao Za Zhi; 2022 Nov; 47(22):5965-5977. PubMed ID: 36471922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases.
    Pandian SRK; Vijayakumar KK; Murugesan S; Kunjiappan S
    Heliyon; 2022 Jun; 8(6):e09575. PubMed ID: 35706935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Therapeutic Benefits of Intravenously Administrated Nanoparticles in Stroke and Age-related Neurodegenerative Diseases.
    Farhoudi M; Sadigh-Eteghad S; Mahmoudi J; Farjami A; Mahmoudian M; Salatin S
    Curr Pharm Des; 2022; 28(24):1985-2000. PubMed ID: 35676838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEG length effect of peptide-functional liposome for blood brain barrier (BBB) penetration and brain targeting.
    Du Q; Liu Y; Fan M; Wei S; Ismail M; Zheng M
    J Control Release; 2024 Jun; 372():85-94. PubMed ID: 38838784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies.
    Loureiro JA; Gomes B; Coelho MA; do Carmo Pereira M; Rocha S
    Nanomedicine (Lond); 2014 Apr; 9(5):709-22. PubMed ID: 24827845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease.
    Agrawal M; Ajazuddin ; Tripathi DK; Saraf S; Saraf S; Antimisiaris SG; Mourtas S; Hammarlund-Udenaes M; Alexander A
    J Control Release; 2017 Aug; 260():61-77. PubMed ID: 28549949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiopep-2 modified dual drug-loaded liposomes with brain targeting functionality mitigate Alzheimer's disease-related symptoms in APP/PS-1 mice.
    Zhang X; Shi N; Chen M; Liu M; Ju R; Liu Y; Kong L; Yu Y; Li X
    J Drug Target; 2023 Jul; 31(6):634-645. PubMed ID: 37203195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesoporous silica nanoparticles: Their potential as drug delivery carriers and nanoscavengers in Alzheimer's and Parkinson's diseases.
    Attia MS; Yahya A; Monaem NA; Sabry SA
    Saudi Pharm J; 2023 Mar; 31(3):417-432. PubMed ID: 37026045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomes: Novel Drug Delivery Approach for Targeting Parkinson's Disease.
    Kumar B; Pandey M; Pottoo FH; Fayaz F; Sharma A; Sahoo PK
    Curr Pharm Des; 2020; 26(37):4721-4737. PubMed ID: 32003666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Advancements in Liposome-Based Strategies for Effective Drug Delivery to the Brain.
    Zamani P; Penson PE; Barreto GE; Sahebkar A
    Curr Med Chem; 2021; 28(21):4152-4171. PubMed ID: 33342401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposome based drug delivery as a potential treatment option for Alzheimer's disease.
    Hernandez C; Shukla S
    Neural Regen Res; 2022 Jun; 17(6):1190-1198. PubMed ID: 34782553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Approaches and Success of Liposome-Based Nano Drug Carriers for the Treatment of Brain Tumor.
    Shaw TK; Paul P
    Curr Drug Deliv; 2022; 19(8):815-829. PubMed ID: 34961462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Focused Ultrasound-mediated Drug Delivery in Humans - a Path Towards Translation in Neurodegenerative Diseases".
    Wasielewska JM; White AR
    Pharm Res; 2022 Mar; 39(3):427-439. PubMed ID: 35257286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimized liposomes with transactivator of transcription peptide and anti-apoptotic drugs to target hippocampal neurons and prevent tau-hyperphosphorylated neurodegeneration.
    Kuo YC; Chen CL; Rajesh R
    Acta Biomater; 2019 Mar; 87():207-222. PubMed ID: 30716553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: Focus on recent advances.
    Niu X; Chen J; Gao J
    Asian J Pharm Sci; 2019 Sep; 14(5):480-496. PubMed ID: 32104476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transferrin-modified liposome promotes α-mangostin to penetrate the blood-brain barrier.
    Chen ZL; Huang M; Wang XR; Fu J; Han M; Shen YQ; Xia Z; Gao JQ
    Nanomedicine; 2016 Feb; 12(2):421-30. PubMed ID: 26711963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): A current overview of active targeting in brain diseases.
    Teixeira MI; Lopes CM; Amaral MH; Costa PC
    Colloids Surf B Biointerfaces; 2023 Jan; 221():112999. PubMed ID: 36368148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanobiotechnology-based drug delivery in brain targeting.
    Dinda SC; Pattnaik G
    Curr Pharm Biotechnol; 2013; 14(15):1264-74. PubMed ID: 24910011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.